NCT07132983View on ClinicalTrials.gov

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

February 23, 2026

Study Completion Date

February 23, 2026

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Ensifentrine 3 mg

Single dose, administered by oral inhalation using a standard jet nebulizer

DRUG

Glycopyrrolate 42.5 mcg

Single dose, administered by oral inhalation using a standard jet nebulizer

DRUG

Ensifentrine 1.5 mg

Single dose, administered by oral inhalation using a standard jet nebulizer

DRUG

Ensifentrine 3 mg (marketed formulation)

Single dose, administered by oral inhalation using a standard jet nebulizer

Trial Locations (4)

63301

RECRUITING

Midwest Chest Consultants PC, Saint Charles

33765-2616

RECRUITING

Clinical Research of West Florida Inc - Clearwater, Clearwater

33606-1246

RECRUITING

Clinical Research of West Florida Inc - Tampa, Tampa

29303-4225

RECRUITING

Velocity Clinical Research - Spartanburg - PPDS, Spartanburg

All Listed Sponsors
lead

Verona Pharma plc

INDUSTRY

NCT07132983 - A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter